I te 13 o Poutū-te-rangi, 2025, i whakaputa te hautaka o te ao rongonui, a Nature Medicine, i te whakamātautau a MediLink mō te B7-H3 targeting antibody drug conjugate (ADC) YL201 Phase 1/1b.
I roto i te whakamātautau, i whakaurua he wāhanga whakanui horopeta (wāhanga 1) me te wāhanga whakawhānui horopeta (wāhanga 1b). E 312 ngā tūroro katoa i whakaurua mai i roto i ngā momo pukupuku maha, tae atu ki te mate pukupuku pūkahukahu iti wāhanga whānui (ES-SCLC), te mate pukupuku ihu (NPC), te mate pukupuku pūkahukahu kore-pūkahukahu iti, te mate pukupuku pūtau squamous esophageal me ētahi atu pukupuku totoka.
I roto i ngā tūroro 287 i arotakengia mō te whai huatanga, ko te auau urupare whāinga (ORR) he 40.8%, ā, ko te auau whakahaere mate (DCR) he 83.6%. Ko te roanga oranga kore-haere whakamua (mPFS) he 5.9 marama, ā, ko te roanga urupare toharite (mDOR) he 6.3 marama. Kāore i te pakeke te roanga oranga whānui (OS).
I roto i ngā tūroro 48 kua horapa te mate ki te roro, 21 i taea te aromatawai; ko te ORR o roto o te angaanga he 28.5%; ā, ko te DOR he 6.2 marama.
I mua i te maimoatanga o ngā tūroro katoa me te ES-SCLC ki te chemotherapy e hangai ana ki te platinum, ā, 95.8% o ngā tūroro i mua i te maimoatanga ki te paturopi mate kua whakaritea 1 (PD-1) me te paturopi ligand mate kua whakaritea 1 (PD-L1) rānei. Ko te ORR he 63.9%; ko te DCR he 91.7%; ko te mPFS he 6.3 marama; ā, ko te mDOR he 5.7 marama. I roto i te rangahau whakanui horopeta, e rima ngā tūroro me te SCLC i whiwhi maimoatanga o mua ki te aukati topoisomerase 1 (topotecan, irinotecan rānei) i whakaurua, ā, kotahi anake te tūroro i whakautu (ORR, 20%). O ngā tūroro 70 me te NPC, i mua i te maimoatanga ki te anti-PD-L1 me te chemotherapy e hangai ana ki te platinum, ā, 84.3% (59/70) he rua, neke atu rānei ngā raina o ngā maimoatanga pūnaha o mua. Tokorua o ngā tūroro me te NPC i tutuki i te urupare katoa (CR), me te ORR o te 48.6% me te DCR o te 92.9%. Ko te mPFS he 7.8 marama, ā, ko te mDOR he 8.4 marama. I arotakehia te katoa o ngā tūroro 64 me te NSCLC momo-mohoao, tae atu ki te 28 me te adenocarcinoma, 12 me te squamous cell carcinoma me te 24 me te lymphoepithelioma-like carcinoma (LELC). I te katoa, 90.6% (58/64) o ngā tūroro me te NSCLC i mua i te maimoatanga ki te anti-PD-L1 me te chemotherapy platinum-based. Ko ngā uara ORR mō ngā tūroro me te adenocarcinoma pūkahukahu, te squamous cell carcinoma me te LELC he 28.6%, 8.3% me te 54.2%, ia, ā, ko te mDOR he 13.6 marama, 2.6 marama me te 6.7 marama, ia.
I whakaatuhia e te YL201 he āhua haumaru e whakaaetia ana, ā, he whai huatanga whakamīharo hoki i roto i ngā tūroro i mua i te maimoatanga nui me ngā pukupuku totoka kua whanake haere, inā koa ko te hunga he ES-SCLC, NPC, he lymphoepithelioma-like carcinoma rānei.
He ADC hou a YL201 kei roto ko te paturopi monoclonal anti-B7H3 tangata kua honoa ki te aukati topoisomerase 1 hou mā te hononga protease-cleavable, me te ōwehenga rongoā-ki-te-antibody o te 8. I whakawhanakehia a YL201 mā te whakamahi i te tūāpapa hononga-utu whakahohe taiao moroiti pukupuku (TMALIN) a MediLink, e tohuhia ana e te kawenga hononga-utu hydrophilic tino, te pumau whakamiharo i roto i te tohanga toto me te tikanga tuku kawenga takirua e uru ana ki te tapahi i waho o te taiao moroiti pukupuku me roto o te pūtau i roto i ngā lysosomes. I roto i tētahi rangahau haumanu-mua, i whakaatuhia e YL201 te kaha anti-pukupuku i roto i ngā tauira kiore CDX/PDX me SCLC, NSCLC, mate pukupuku korokoro me te mate pukupuku ovarian. Ko ngā raraunga whai huatanga me te haumaru mai i tēnei rangahau haumanu-mua e kī ana he taurite pai te painga-mōrearea, e tautoko ana i te whanaketanga tonu o YL201 i roto i te whare hauora.
I tēnei wā, he maha tonu ngā whakamātautau haumanu o ngā hangarau hou hei ārai i te matepukupuku i Haina e rapu ana i ngā tūroro. Mēnā kei te hiahia koe ki te kōrero mō ngā rongoā me ngā hangarau hou, ka taea e koe te whakapā atu ki te Tari Ao o te Hōhipera Oncology Rohe Tonga o Beijing.
Tau Waea：4008803716
Email：myimmnet@163.com
Wā tuku: Paenga-whāwhā-08-2025